Envoy Medical Announces Publication of Additional Patent for Implantable Cochlear Systems
10 Novembre 2023 - 3:00PM
Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a
revolutionary hearing health company focused on fully implanted
hearing systems, today announced that it has been awarded another
patent. This patent – “Implantable Cochlear System with Inner Ear
Sensor” (Document ID: US 11806531 B2) – is one of a growing
number of patents that Envoy Medical has applied for or secured as
part of its implantable hearing devices technology portfolio.
“We are excited to announce this new patent, which gives us an
additional opportunity to evolve and grow our designs over time.
We’ve made no secret of our intent to disrupt the hearing implant
market with our fully implanted Acclaim® cochlear implant, but we
also have a strategy to maintain that momentum with additional
advances in the implantable hearing device market for years to
come,” said Brent Lucas, Envoy Medical’s Chief Executive
Officer.
About Envoy Medical
Envoy Medical, Inc. (NASDAQ: COCH), headquartered in White Bear
Lake, Minnesota, is a hearing health company focused on providing
innovative medical technologies.
Envoy Medical is dedicated to pushing hearing technology beyond
the status quo to provide patients with improved access, usability,
independence and quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant will be
a first-of-its-kind fully implanted cochlear implant. Envoy
Medical’s fully implanted technology includes a sensor designed to
leverage the natural anatomy of the ear instead of a microphone to
capture sound.
The Acclaim is designed to address severe to profound
sensorineural hearing loss that is not adequately addressed by
hearing aids. The Acclaim is expected to be indicated for adults
who have been deemed adequate candidates by a qualified
physician.
The Acclaim Cochlear Implant received the Breakthrough Device
Designation from the U.S. Food and Drug Administration (FDA) in
2019. We believe the Acclaim was the first hearing-focused device
to receive Breakthrough Device Designation.
CAUTION The fully implanted Acclaim Cochlear Implant is an
investigational device. Limited by United States law to
investigational use.
Important safety information for the Esteem can be found at:
https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may
be obtained free of charge at the SEC’s website at www.sec.gov.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-Looking
statements may be identified by the use of words such as
“estimate,” “plan,” “project,” “forecast,” “intend,” “will,”
“expect,” “anticipate,” “believe,” “seek,” “target” or other
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters, but the
absence of these words does not mean that a statement is not
forward-looking. Such statements may include, but are not limited
to, statements regarding the expectations of Envoy Medical
concerning the outlook for its business, productivity, plans and
goals for future operational improvements and capital investments,
the ability to obtain additional patents and develop future
products or product improvements, clinical testing timeline and
results, the benefits of the Acclaim device compared to existing
cochlear implants, the Acclaim being the first to market fully
implanted cochlear implant, the size of Envoy Medical’s addressable
market, operational performance, future market conditions or
economic performance and developments in the capital and credit
markets, as well as any information concerning possible or assumed
future operations of Envoy Medical. Forward-looking statements also
include statements regarding the expected benefits of the Nasdaq
listing. The forward-looking statements contained in this press
release reflect Envoy Medical’s current views about future events
and are subject to numerous known and unknown risks, uncertainties,
assumptions and changes in circumstances that may cause its actual
results to differ significantly from those expressed in any
forward-looking statement. Envoy Medical does not guarantee that
the transactions and events described will happen as described (or
that they will happen at all). These forward-looking statements are
subject to a number of risks and uncertainties, including, but not
limited to Envoy Medical’s performance following its business
combination transaction, which closed September 29, 2023; changes
in the market price of shares of Envoy Medical’s Class A Common
Stock; Envoy Medical’s success in retaining or recruiting, or
changes required in, its officers, key employees or directors;
unpredictability in the medical device industry, the regulatory
process to approve medical devices, and the clinical development
process of Envoy Medical products; competition in the medical
device industry, and the failure to introduce new products and
services in a timely manner or at competitive prices to compete
successfully against competitors; disruptions in relationships with
Envoy Medical’s suppliers, or disruptions in Envoy Medical’s own
production capabilities for some of the key components and
materials of its products; changes in the need for capital and the
availability of financing and capital to fund these needs; changes
in interest rates or rates of inflation; legal, regulatory and
other proceedings could be costly and time-consuming to defend;
changes in applicable laws or regulations, or the application
thereof on Envoy Medical; a loss of any of Envoy Medical’s key
intellectual property rights or failure to adequately protect
intellectual property rights; the effects of catastrophic events,
including war, terrorism and other international conflicts; and
other risks and uncertainties set forth in the section entitled
“Risk Factors” and “Cautionary Note Regarding Forward Looking
Statements” in the Registration Statement on Form S-4 (File
No. 333-271920) filed by Envoy Medical (then known as Anzu Special
Acquisition Corp I), and in other reports Envoy Medical files
with, the SEC. If any of these risks materialize or Envoy Medical’s
assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. While
forward-looking statements reflect Envoy Medical’s good faith
beliefs, they are not guarantees of future performance. Envoy
Medical disclaims any obligation to publicly update or revise any
forward-looking statement to reflect changes in underlying
assumptions or factors, new information, data or methods, future
events or other changes after the date of this press release,
except as required by applicable law. You should not place undue
reliance on any forward-looking statements, which are based only on
information currently available to Envoy Medical.
###
Investor Contact:
Matt KrepsDarrow Associates Investor Relations(214)
597-8200mkreps@darrowir.com
Grafico Azioni Envoy Medical (NASDAQ:COCH)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Envoy Medical (NASDAQ:COCH)
Storico
Da Giu 2023 a Giu 2024